Ignite Creation Date:
2024-07-17 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06464133
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
2024-06-18
First Post:
2024-05-10
Brief Title:
Investigation of Filaggrin Gene Mutations Among Latinx Patients With Atopic Dermatitis
Sponsor:
University of Pennsylvania
Organization:
University of Pennsylvania
Study Overview
Official Title:
Investigation of Filaggrin Gene Mutations Among Latinx Patients With Atopic Dermatitis
Status:
ENROLLING_BY_INVITATION
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study Investigation of Filaggrin Gene Mutations among Latinx patients with Atopic Dermatitis will examine the association between pathogenic FLG LOF variants and AD in a new population of Latinx patients for which clinical and disease characteristics will be well-described
Detailed Description:
Filaggrin deficiency is considered a major target for therapy in Atopic Dermatitis AD43 The current status quo with regards to FLG LOF mutations as the strongest known genetic risk factor in AD stems from incomplete data as the majority of studies that have previously examined this association have been carried out in only a limited group of populations ie European ancestry30 Such partial data impedes our full understanding of genetic risk in AD and consequently has implications for disease prognosis and management The proposed research represents an attempt to examine long-held paradigms in AD as they relate to genetic risk factors and disease The development of an independent cohort of Latinx subjects with physician-confirmed diagnosis of AD that is also well phenotyped and grouped by ancestry while also capturing measures of disease severity will provide the opportunity to examine a population that has been largely absent from prior studies and further advance our understanding of the pathogenomic role FLG LOF variants in AD
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None